Abstract
We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1. He was diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy. We selected combined chemotherapy with both paclitaxel and S-1. Paclitaxel at 60 mg/m2 was administered intraperitoneally on days 1 and 8, and S-1 at 100 mg/body was administered orally for 14 days, followed by 7 days’ rest, as one course. After five courses, primary tumor reduction was confirmed and no cancer cells were detected on pathocytological investigation at second-look laparoscopy. The patient underwent total gastrectomy with lymph node dissection. He died from liver metastasis 29 months after the initial treatment, but he had not suffered from peritoneal metastases and had kept a good quality of life (QOL) since that treatment. This chemotherapy can be applied as one of the promising candidates for the treatment of patients with peritoneal metastasis of gastric cancer.
Article PDF
Similar content being viewed by others
References
Y Yonemura T Sawa K Kinoshita N Matsuki S Fushida S Tanaka et al. (1993) ArticleTitleNeoadjuvant chemotherapy for high-grade advanced gastric cancer World J Surg 17 256–62 Occurrence Handle8511923 Occurrence Handle10.1007/BF01658939 Occurrence Handle1:STN:280:DyaK3s3ovFOluw%3D%3D
PH Sugerbaker Y Yonemura (2000) ArticleTitleClinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure Oncology 58 96–107 Occurrence Handle10.1159/000012086
S Fujimoto M Takahashi K Kobayashi M Kure T Mutou H Masaoka et al. (1993) ArticleTitleRelation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis Oncology 50 338–43 Occurrence Handle8378028 Occurrence Handle1:STN:280:DyaK3szptVyksg%3D%3D Occurrence Handle10.1159/000227206
E Nomura M Niki K Fujii H Shinohara K Nishiguchi T Sonoda (2001) ArticleTitleEfficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer Gastric Cancer 4 75–82 Occurrence Handle11706764 Occurrence Handle10.1007/PL00011727 Occurrence Handle1:CAS:528:DC%2BD3MXosFChurY%3D
T Shirasaka Y Shimamoto H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle10.1097/00001813-199607000-00010 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study on novel oral fluoropyrimidine anticancer drug S-1 (IM Tegafur-0.4M Gimestat-1M Otastat Potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
T Mori Y Fujiwara M Yano S Tamura T Yasuda S Takiguchi et al. (2003) ArticleTitlePrevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil Oncology 64 176–82 Occurrence Handle12566916 Occurrence Handle10.1159/000067774 Occurrence Handle1:CAS:528:DC%2BD3sXntFShtw%3D%3D
EK Rowinsky RC Donehower RJ Jones RW Tucker (1988) ArticleTitleMicrotubule changes and cytotoxicity in leukemic cell lines treated with Taxol Cancer Res 48 4093–100 Occurrence Handle2898289 Occurrence Handle1:CAS:528:DyaL1cXkvVGrurc%3D
M Markman E Rowinsky T Harkes B Reichman W Jones JL Lewis SuffixJr et al. (1992) ArticleTitlePhase I trial of intraperitoneal Taxol: a Gynecoloic Oncology Group Study J Clin Oncol 10 1485–91 Occurrence Handle1355523 Occurrence Handle1:STN:280:DyaK38zovV2luw%3D%3D
InstitutionalAuthorNameJapanese Gastric Cancer Association (1998) ArticleTitleJapanese classification of gastric carcinoma. 2nd English ed Gastric Cancer 1 25–30 Occurrence Handle10.1007/PL00011681
T Konishi M Hiraishi K Mafune T Miyama T Hirata K Mori et al. (1994) ArticleTitleTherapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer Anticancer Res 14 1277–80 Occurrence Handle8067696 Occurrence Handle1:STN:280:DyaK2czks1OmtA%3D%3D
M Tahara A Ohotsu N Boku F Nagashima M Muto Y Sano et al. (2001) ArticleTitleSequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study Gastric Cancer 4 212–8 Occurrence Handle11846065 Occurrence Handle10.1007/s10120-001-8012-x Occurrence Handle1:CAS:528:DC%2BD38XislCksbc%3D
H Osugi N Takada M Takemura S Kaseno S Lee M Ueno et al. (2002) ArticleTitleOral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination Oncol Rep 9 811–5 Occurrence Handle12066214 Occurrence Handle1:CAS:528:DC%2BD38XltlGrsrk%3D
P Francis E Rowinsky J Schneider T Hakes W Hoskins M Markman (1995) ArticleTitlePhase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study J Clin Oncol 13 2961–7 Occurrence Handle8523061 Occurrence Handle1:CAS:528:DyaK28XmslOmtw%3D%3D
M Markman MF Brady NM Spirtos P Hanjani SC Rubin (1998) ArticleTitlePhase II trial of intraperitoneal Taxol in carcinoma of the ovary, tube, and peritoneum: a Gynecoloic Oncology Group Study J Clin Oncol 16 1485–91
S Fushida N Furui S Kinami I Ninomiya T Fujimura G Nishimura et al. (2002) ArticleTitlePharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination (in Japanese) Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 29 2164–7
Y Yonemura Y Endou E Bando K Kuno T Kawamura M Kimura et al. (2004) ArticleTitleEffect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer Cancer Lett 210 189–96 Occurrence Handle15183534 Occurrence Handle10.1016/j.canlet.2004.03.018 Occurrence Handle1:CAS:528:DC%2BD2cXks1WrsLc%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tamura, S., Miki, H., Nakata, K. et al. Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer 10, 251–255 (2007). https://doi.org/10.1007/s10120-007-0431-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-007-0431-x